종양내 주사 요법 시장 : 전략적 인사이트 및 예측(2026-2031년)

The Intratumoral Injection Therapy Market is set to reach USD 630.39 million in 2031, growing at a CAGR of 3.8 % from USD 418.98 million in 2026.

The global intratumoral injection therapy market is experiencing rapid expansion as pharmaceutical companies, biotechnology firms, oncology centers, and research institutions increasingly focus on therapies that deliver therapeutic agents directly into tumors. Intratumoral injection therapy involves localized administration of immunotherapies, oncolytic viruses, cytokines, gene therapies, monoclonal antibodies, and other therapeutic agents into the tumor microenvironment to stimulate targeted anti-tumor responses while reducing systemic adverse effects. This therapeutic approach is gaining substantial traction across oncology because of its ability to enhance local immune activation, improve therapeutic precision, and potentially trigger systemic immune responses through the abscopal effect.

The increasing global burden of cancer remains one of the primary drivers supporting market growth. Rising incidence of melanoma, lung cancer, breast cancer, prostate cancer, pancreatic cancer, head and neck cancer, and other solid tumors continues increasing demand for targeted and minimally invasive oncology therapies. Conventional systemic therapies often cause substantial toxicity and treatment resistance, encouraging adoption of localized therapeutic strategies such as intratumoral injection therapies.

The rapid expansion of immuno-oncology and tumor microenvironment research is another major factor accelerating market development. Intratumoral therapies are increasingly utilized to convert immunologically "cold" tumors into "hot" tumors capable of generating stronger immune responses. Direct tumor injection enhances local antigen release, activates immune cell infiltration, and improves responsiveness to systemic immunotherapies such as immune checkpoint inhibitors.

The growing development of oncolytic viral therapies is significantly reshaping the market landscape. Oncolytic viruses selectively infect and destroy tumor cells while stimulating anti-tumor immune activity. Several biotechnology companies and pharmaceutical organizations are actively advancing intratumoral oncolytic virus platforms across multiple oncology indications. Clinical success and ongoing pipeline expansion continue strengthening commercial interest in intratumoral injection-based therapies.

Advancements in precision oncology and biomarker-driven treatment strategies are further supporting market growth. Molecular diagnostics, genomic profiling, AI-powered analytics, and companion diagnostics are increasingly utilized to identify patients likely to benefit from localized intratumoral therapies. Precision medicine integration is improving therapeutic targeting and enhancing clinical trial optimization across oncology research programs.

The increasing focus on combination therapies is another important trend shaping the market. Researchers are increasingly evaluating intratumoral injection therapies in combination with immune checkpoint inhibitors, chemotherapy, radiotherapy, CAR-T therapies, and targeted therapies to improve overall treatment efficacy. Combination-based immunotherapy strategies are demonstrating promising clinical outcomes across several difficult-to-treat solid tumors.

The market is also benefiting from advancements in image-guided drug delivery and minimally invasive interventional oncology procedures. Ultrasound-guided injections, CT-guided procedures, endoscopic injection systems, and precision delivery devices are improving therapeutic accuracy and reducing procedural risks associated with intratumoral administration. Image-guided interventional oncology technologies continue supporting broader clinical adoption of localized cancer therapies.

Artificial intelligence and digital healthcare technologies are increasingly transforming intratumoral therapy development and clinical implementation. AI-powered imaging analytics, predictive biomarker identification, computational biology platforms, and digital monitoring systems are improving patient selection, therapy optimization, and clinical trial efficiency. These technologies are accelerating innovation across the localized oncology treatment ecosystem.

The increasing investment in oncology clinical trials and translational research is another major factor supporting market expansion. Biotechnology firms, academic research centers, and pharmaceutical companies continue expanding clinical development programs focused on cytokine therapies, gene therapies, immune modulators, adoptive cell therapies, and oncolytic viruses delivered through intratumoral injection. Collaborative oncology research initiatives are accelerating innovation and commercialization opportunities.

North America currently dominates the intratumoral injection therapy market due to advanced oncology infrastructure, strong immunotherapy adoption, extensive clinical trial activity, and substantial biotechnology investment. Europe also represents a significant market supported by expanding precision oncology programs and increasing cancer research collaboration. Asia Pacific is expected to witness rapid growth due to rising cancer prevalence, healthcare modernization, expanding biotechnology ecosystems, and increasing oncology research investment across countries such as China, Japan, India, and South Korea.

Despite strong growth prospects, the market faces challenges related to complex delivery procedures, high development costs, limited long-term clinical data, tumor accessibility constraints, and regulatory uncertainties. However, ongoing advancements in oncolytic virotherapy, precision medicine, biomarker-guided therapeutics, and image-guided delivery technologies are expected to create substantial long-term growth opportunities for the intratumoral injection therapy market.

Market Drivers

Rising Demand for Localized Cancer Therapies

The increasing need for therapies capable of minimizing systemic toxicity while improving therapeutic precision is one of the primary drivers supporting market growth.

Intratumoral injection therapies enable high local drug concentration within tumors while reducing adverse systemic exposure.

Expansion of Immuno-Oncology Research

Growing research focused on tumor microenvironment modulation and immune activation is accelerating development of intratumoral immunotherapies.

Localized immune stimulation strategies continue improving therapeutic innovation across oncology care settings.

Increasing Development of Oncolytic Viral Therapies

Oncolytic viruses are gaining substantial attention because of their ability to selectively destroy tumor cells while activating anti-tumor immunity.

Pipeline expansion continues strengthening market growth potential.

Advancements in Image-Guided Drug Delivery

Ultrasound-guided, CT-guided, and endoscopic injection systems are improving precision and safety of intratumoral therapeutic administration.

Interventional oncology advancements continue supporting clinical adoption.

Increasing Combination Therapy Development

Researchers increasingly evaluate intratumoral therapies alongside checkpoint inhibitors, chemotherapy, and targeted therapies to improve treatment efficacy.

Combination immunotherapy strategies continue accelerating oncology innovation.

Market Restraints

Complex Administration Procedures

One of the major restraints affecting the market is the technical complexity associated with direct tumor injection and image-guided delivery procedures.

Procedural limitations may restrict broader clinical implementation.

Limited Accessibility for Certain Tumor Types

Not all tumors are anatomically accessible for intratumoral administration, limiting treatment applicability across some cancer indications.

Tumor accessibility challenges may affect patient eligibility.

High Research and Development Costs

Development of localized oncology therapies requires extensive clinical validation, biomarker research, and specialized delivery technologies.

High development costs may create commercialization barriers.

Limited Long-Term Clinical Data

Several intratumoral therapies remain under clinical investigation with limited long-term efficacy and safety evidence currently available.

Regulatory and adoption challenges may persist until broader clinical evidence emerges.

Technology and Segment Insights

The intratumoral injection therapy market is segmented by therapy type, cancer type, delivery technology, end-user, and geography. By therapy type, the market includes oncolytic viruses, cytokine therapies, monoclonal antibodies, gene therapies, checkpoint inhibitors, immune modulators, and adoptive cell therapies. Oncolytic viruses currently represent one of the fastest-growing segments because of strong pipeline activity and increasing clinical validation.

Monoclonal antibodies and cytokine-based therapies also account for substantial market share because of increasing utilization within immuno-oncology frameworks.

Based on cancer type, the market includes melanoma, breast cancer, lung cancer, head and neck cancer, pancreatic cancer, prostate cancer, and others. Melanoma currently dominates the market because of strong immunotherapy responsiveness and extensive clinical research involving localized immune activation strategies.

Head and neck cancer and pancreatic cancer are also witnessing increasing research activity because of unmet therapeutic needs and resistance to conventional therapies.

By delivery technology, the market includes image-guided injection systems, endoscopic delivery systems, intraoperative administration technologies, and minimally invasive interventional oncology platforms. Image-guided injection technologies currently dominate the market because of increasing emphasis on precision delivery and procedural safety.

Based on end-user, the market includes hospitals, specialty oncology clinics, cancer research institutes, and academic medical centers. Hospitals and cancer centers currently account for the largest market share because of advanced oncology infrastructure and multidisciplinary treatment capabilities.

Academic research organizations continue contributing significantly through translational oncology research and clinical trial expansion.

Regionally, North America currently dominates the market due to strong biotechnology ecosystems, advanced immunotherapy adoption, and extensive clinical development activities. Europe also represents a major market supported by increasing oncology research collaboration and precision medicine integration.

Asia Pacific is expected to witness rapid growth due to expanding biotechnology investment, healthcare modernization, and rising oncology treatment demand.

Competitive and Strategic Outlook

The intratumoral injection therapy market is highly competitive and characterized by the presence of biotechnology companies, pharmaceutical organizations, immunotherapy developers, and interventional oncology providers. Key market participants include Replimune Group, Inc., Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc., Bristol Myers Squibb Company, OncoSec Medical Incorporated, Nanobiotix S.A., DNAtrix, Sirnaomics Ltd., and Intensity Therapeutics, Inc.

Leading organizations are increasingly focusing on oncolytic viral therapies, immune modulators, localized cytokine therapies, AI-powered biomarker discovery, and combination immunotherapy strategies to strengthen market positioning. Investments in tumor microenvironment research, precision oncology, and minimally invasive delivery technologies continue accelerating across the industry.

Strategic collaborations between biotechnology firms, pharmaceutical companies, academic institutions, and oncology centers are improving clinical trial capabilities and therapeutic development efficiency. Partnerships involving checkpoint inhibitors, personalized immunotherapy, and image-guided oncology platforms are becoming increasingly common.

The market is witnessing increasing emphasis on localized immunotherapy, biomarker-guided treatment selection, AI-enabled therapeutic optimization, and precision oncology integration. Organizations capable of improving delivery precision, clinical efficacy, safety profiles, and scalability are expected to strengthen long-term market competitiveness.

Conclusion

The intratumoral injection therapy market is expected to witness substantial growth due to rising demand for localized cancer therapies, expanding immuno-oncology research, and increasing development of oncolytic viral therapies and tumor microenvironment-targeted treatments.

Advancements in image-guided delivery systems, precision medicine, AI-powered analytics, biomarker-driven oncology, and combination immunotherapy strategies are significantly transforming localized cancer treatment frameworks. Healthcare systems and biotechnology organizations increasingly prioritize targeted therapies capable of improving therapeutic efficacy while minimizing systemic toxicity.

The market continues to face challenges related to procedural complexity, tumor accessibility, high development costs, and limited long-term clinical data. However, ongoing innovation in immunotherapy, interventional oncology, oncolytic virotherapy, and precision drug delivery technologies is expected to create substantial long-term growth opportunities for the intratumoral injection therapy market.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

1.1Intratumoral Injection Therapy Market Definition and Scope

• 1.2 Therapeutic Modality Overview
• 1.3 Key Approved Therapies and Developer Companies Overview
• 1.4 Clinical Value Proposition vs Systemic Therapies
• 1.5 Market Size Snapshot and Growth Outlook
• 1.6 Strategic Insights

2. Disease & Patient Population Intelligence

• 2.1 Target Indications for Intratumoral Injection Therapy Market
  • 2.1.1 Melanoma
  • 2.1.2 Head and Neck Squamous Cell Carcinoma
  • 2.1.3 Breast Cancer
  • 2.1.4 Liver Cancer
  • 2.1.5 Other Solid Tumours with Injectable Lesions
• 2.2 Epidemiology Modelling Framework
  • 2.2.1 Total Cancer Incidence
  • 2.2.2 Diagnosed Population
  • 2.2.3 Patients with Injectable/Accessible Tumors
  • 2.2.4 Eligible Population for Intratumoral Injection Therapy Market
• 2.3 Patient Segmentation
  • 2.3.1 Tumor Accessibility
  • 2.3.2 Biomarker Segmentation
  • 2.3.3 Disease Stage
  • 2.3.4 Line of Therapy
• 2.4 Treatment Pathway Integration
  • 2.4.1 Combination with Immunotherapy
  • 2.4.2 Use in Refractory Disease
  • 2.4.3 Role in Multimodal Treatment

3. Market Dynamics

• 3.1 Market Drivers
• 3.2 Market Restraints
• 3.3 Market Opportunities
• 3.4 Market Challenges

4. Pharmacological & Mechanistic Landscape

• 4.1 Definition and Classification of Intratumoral Injection Therapy Market
• 4.2 Mechanisms of Action
  • 4.2.1 Oncolytic Viral Therapy
  • 4.2.2 Immune Activation and Cytokine Release
  • 4.2.3 Tumor Microenvironment Modulation
• 4.3 Biological Pathways
  • 4.3.1 Innate Immune Activation
  • 4.3.2 Adaptive Immune Response
  • 4.3.3 Checkpoint Pathway Synergy
• 4.4 Competitive Mechanism Benchmarking
  • 4.4.1 vs Systemic Immunotherapy
  • 4.4.2 vs Chemotherapy and Radiotherapy
  • 4.4.3 Combination Strategies
• 4.5 Resistance Mechanisms
• 4.6 Safety and Tolerability Comparison

5. Clinical Outcomes & Evidence Benchmarking

• 5.1 Clinical Development Framework
• 5.2 Key Clinical Endpoints
  • 5.2.1 Objective Response Rate
  • 5.2.2 Durable Response Rate
  • 5.2.3 Progression-Free Survival
  • 5.2.4 Overall Survival
  • 5.2.5 Local Tumor Control
• 5.3 Landmark Clinical Trials
  • 5.3.1 OPTiM Trial (Talimogene Laherparepvec)
• 5.4 Head-to-Head and Combination Studies
• 5.5 Real-World Evidence
• 5.6 Safety Profile Benchmarking

6. Pipeline & Innovation Landscape

• 6.1 Pipeline Overview by Phase
• 6.2 Key Pipeline Therapies and Developer Companies
• 6.3 Innovation Trends
• 6.4 Probability of Success by Phase
• 6.5 Expected Launch Timelines
• 6.6 Clinical Trial Landscape

7. Regulatory & Market Access Intelligence

• 7.1 Regulatory Approval Pathways
  • 7.1.1 United States FDA
  • 7.1.2 European Medicines Agency
  • 7.1.3 PMDA Japan
  • 7.1.4 CDSCO India
• 7.2 Advanced Therapy Classification
• 7.3 Companion Diagnostics Requirements
• 7.4 Pricing and Reimbursement Landscape
• 7.5 Health Technology Assessment Considerations
• 7.6 Access Barriers

8. Intratumoral Injection Therapy Market Size, Utilisation & Forecast

• 8.1 Intratumoral Injection Therapy Market Size
• 8.2 Historical Trends
• 8.3 Forecast (2026-2031)
• 8.4 Treated Patient Volume
• 8.5 Procedure Volume
• 8.6 Adoption Curve Analysis
• 8.7 Pricing Benchmarking
• 8.8 Revenue Contribution by Therapy Type

9. Intratumoral Injection Therapy Market Segmentation

• 9.1 By Therapy Type
  • 9.1.1 Oncolytic Viruses
  • 9.1.2 Cytokine-Based Therapies
  • 9.1.3 Gene Therapy Approaches
  • 9.1.4 Immunomodulators
• 9.2 By Indication
  • 9.2.1 Melanoma
  • 9.2.2 Head and Neck Cancer
  • 9.2.3 Breast Cancer
  • 9.2.4 Liver Cancer
  • 9.2.5 Other Solid Tumors
• 9.3 By Line of Therapy
  • 9.3.1 First-Line
  • 9.3.2 Second-Line
  • 9.3.3 Third-Line and Beyond
• 9.4 By End User
  • 9.4.1 Hospitals
  • 9.4.2 Cancer Specialty Clinics
  • 9.4.3 Ambulatory Care Centers

10. Geographical Analysis

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 Latin America
• 10.5 Middle East & Africa

11. Key Countries Analysis

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Strategic Initiatives

13. Company Profiles

• 13.1 Amgen Inc.
  • 13.1.1 Approved Products: Imlygic (talimogene laherparepvec)
  • 13.1.2 Key Indications: Melanoma
  • 13.1.3 Pipeline (Phase I/II/III): Intratumoral combination immunotherapy programs
• 13.2 Daiichi Sankyo Company, Limited
  • 13.2.1 Approved Products: Delytact (teserpaturev)
  • 13.2.2 Key Indications: Malignant glioma
  • 13.2.3 Pipeline (Phase I/II/III): Ongoing clinical development
• 13.3 Nanobiotix
  • 13.3.1 Approved Products: Hensify (NBTXR3)
  • 13.3.2 Key Indications: Soft tissue sarcoma
  • 13.3.3 Pipeline (Phase I/II/III): Solid tumor development programs
• 13.4 Replimune Group, Inc.
  • 13.4.1 Approved Products: None
  • 13.4.2 Key Indications: Melanoma and skin cancers
  • 13.4.3 Pipeline (Phase I/II/III): Oncolytic virus therapies
• 13.5 Oncolytics Biotech Inc.
  • 13.5.1 Approved Products: None
  • 13.5.2 Key Indications: Solid tumours
  • 13.5.3 Pipeline (Phase I/II/III): Viral immunotherapy programs
• 13.6 Genelux Corporation
  • 13.6.1 Approved Products: None
  • 13.6.2 Key Indications: Ovarian cancer
  • 13.6.3 Pipeline (Phase I/II/III): Vaccinia virus-based therapies
• 13.7 Philogen S.p.A.
  • 13.7.1 Approved Products: None
  • 13.7.2 Key Indications: Melanoma
  • 13.7.3 Pipeline (Phase I/II/III): Immunocytokine therapies
• 13.8 Istari Oncology
  • 13.8.1 Approved Products: None
  • 13.8.2 Key Indications: Glioblastoma
  • 13.8.3 Pipeline (Phase I/II/III): Viral immunotherapy
• 13.9 DNAtrix, Inc.
  • 13.9.1 Approved Products: None
  • 13.9.2 Key Indications: Glioblastoma
  • 13.9.3 Pipeline (Phase I/II/III): Adenovirus-based therapies
• 13.10 Regeneron Pharmaceuticals, Inc.
  • 13.10.1 Approved Products: None
  • 13.10.2 Key Indications: Melanoma
  • 13.10.3 Pipeline (Phase I/II/III): TLR9 agonist intratumoral therapy

14. Future Outlook & Strategic Recommendations

• 14.1 Expansion of Combination Therapies
• 14.2 Advances in Delivery Technologies
• 14.3 Competitive Landscape Evolution
• 14.4 Strategic Imperatives
• 14.5 Long-Term Market Opportunity

15. Methodology & Data Framework

• 15.1 Data Sources
• 15.2 Epidemiology Modeling
• 15.3 Market Forecasting Approach
• 15.4 Clinical Benchmarking
• 15.5 Data Validation and Triangulation

16. Appendix

• 16.1 Abbreviations
• 16.2 Definitions
• 16.3 Assumptions